C L Loprinzi

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
    Deirdre R Pachman
    Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Int J Womens Health 2:123-35. 2010
  2. doi request reprint Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain
    Deirdre R Pachman
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:3687-96. 2012
  3. pmc Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
    Lauren E Ta
    Program in Molecular Neuroscience, Mayo Graduate School, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Mol Pain 6:15. 2010
  4. ncbi request reprint The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer J 13:399-403. 2007
  5. pmc Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1
    Charles L Loprinzi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 28:641-7. 2010
  6. ncbi request reprint Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians
    Charles L Loprinzi
    Mayo Clinic, Rochester, Minnesota 550905, USA
    J Natl Compr Canc Netw 1:189-96. 2003
  7. ncbi request reprint Phase III evaluation of fluoxetine for treatment of hot flashes
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1578-83. 2002
  8. ncbi request reprint Tamoxifen-induced hot flashes
    C L Loprinzi
    Mayo Clinic, Mayo Foundation, Rochester, MN, USA
    Clin Breast Cancer 1:52-6. 2000
  9. ncbi request reprint Management of hot flashes in breast-cancer survivors
    C L Loprinzi
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 2:199-204. 2001
  10. ncbi request reprint Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Menopause 15:655-60. 2008

Research Grants

  1. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 1999
  2. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Charles Loprinzi; Fiscal Year: 2006
  3. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Charles Loprinzi; Fiscal Year: 2005
  4. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
  5. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2002
  6. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2001
  7. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2000
  8. CAPITATION
    Charles Loprinzi; Fiscal Year: 2007

Detail Information

Publications114 found, 100 shown here

  1. pmc Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
    Deirdre R Pachman
    Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Int J Womens Health 2:123-35. 2010
    ..Paced respirations and hypnosis appear to be promising enough to warrant further investigation. Another promising nonpharmacological therapy, currently under investigation, involves a stellate ganglion block...
  2. doi request reprint Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain
    Deirdre R Pachman
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:3687-96. 2012
    ..This article will focus on the management of these symptoms, including an assessment of the current research and proposed best- management practices...
  3. pmc Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
    Lauren E Ta
    Program in Molecular Neuroscience, Mayo Graduate School, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Mol Pain 6:15. 2010
    ..The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have demonstrated important roles for TRPV1, TRPM8, and TRPA1 in inflammation and nerve injury induced pain...
  4. ncbi request reprint The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Cancer J 13:399-403. 2007
    ..Herein, we characterize the clinical characteristics of this syndrome using detailed patient interviews and consider the putative mechanism(s) for these symptoms...
  5. pmc Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1
    Charles L Loprinzi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 28:641-7. 2010
    ..Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes...
  6. ncbi request reprint Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians
    Charles L Loprinzi
    Mayo Clinic, Rochester, Minnesota 550905, USA
    J Natl Compr Canc Netw 1:189-96. 2003
    ..Two computer-based tools (Numeracy and Adjuvant!) are available to facilitate this process...
  7. ncbi request reprint Phase III evaluation of fluoxetine for treatment of hot flashes
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1578-83. 2002
    ..Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed...
  8. ncbi request reprint Tamoxifen-induced hot flashes
    C L Loprinzi
    Mayo Clinic, Mayo Foundation, Rochester, MN, USA
    Clin Breast Cancer 1:52-6. 2000
    ....
  9. ncbi request reprint Management of hot flashes in breast-cancer survivors
    C L Loprinzi
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 2:199-204. 2001
    ..Several studies in progress may provide better non-hormonal means of treating hot flashes in the future...
  10. ncbi request reprint Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Menopause 15:655-60. 2008
    ..This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group...
  11. pmc Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic, 200 First St Southwest, Rochester MN 55905, USA
    J Clin Oncol 27:2831-7. 2009
    ..This current project was developed to conduct an individual patient pooled analysis of the data from these published clinical trials...
  12. ncbi request reprint Pilot evaluation of gabapentin for treating hot flashes
    L Loprinzi
    Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1159-63. 2002
    ..To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes...
  13. doi request reprint Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration
    Charles L Loprinzi
    Mayo Clinic, Rochester, MN, USA
    Menopause 16:883-7. 2009
    ..This article is devoted to providing scientific data to better ascertain how long it is necessary to conduct hot flash trials with newer centrally acting agents...
  14. pmc A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)
    C L Loprinzi
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 20:542-9. 2009
    ..Hot flashes represent a significant problem in men undergoing androgen deprivation therapy...
  15. doi request reprint Newer antidepressants for hot flashes--should their efficacy still be up for debate?
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Menopause 16:184-7. 2009
    ..These two studies have repeatedly been put forward as evidence that newer antidepressants are not definitively proven to reduce hot flashes...
  16. pmc Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1472-8. 2011
    ..The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated...
  17. ncbi request reprint Why not start with thalidomide?
    Charles Loprinzi
    Division of Medical Oncology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    J Clin Oncol 21:2211-4. 2003
  18. ncbi request reprint Symptom control trials: a 20-year experience
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Support Oncol 5:119-25, 128. 2007
    ....
  19. pmc A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA
    Charles L Loprinzi
    Mayo Clinic Rochester, Rochester, Minnesota, USA
    J Support Oncol 9:105-12. 2011
    ..This finding was confirmed by other secondary analyses. Toxicity evaluation revealed more nausea, sweating, rigors, and urinary frequency with the pilocarpine arms compared with the placebo arm...
  20. ncbi request reprint Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 56301, USA
    Cancer 104:176-82. 2005
    ..Secondary research goals were to evaluate toxicities, tolerability, and quality of life associated with this shark cartilage product...
  21. ncbi request reprint Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:969-73. 1997
    ..The present trial was developed to evaluate the nonhormonal vaginal lubricating preparation, Replens, for alleviating these symptoms...
  22. ncbi request reprint Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:1235-8. 1997
    ..Pursuant to preliminary data that suggested a sucralfate oral solution could alleviate chemotherapy-induced oral mucositis, we developed a prospective trial to test this contention...
  23. ncbi request reprint Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
    C L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 16:2377-81. 1998
    ..Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem...
  24. ncbi request reprint Doc, shouldn't we be getting some tests?
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:108s-111s. 2003
  25. ncbi request reprint The questions of prognosis
    Charles Loprinzi
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Support Oncol 3:340-1. 2005
  26. ncbi request reprint Pilot evaluation of paroxetine for treating hot flashes in men
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 79:1247-51. 2004
    ..To provide prospective information on the potential utility of paroxetine for treating hot flashes In men receiving androgen ablation therapy for prostate cancer...
  27. ncbi request reprint Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Lancet 356:2059-63. 2000
    ..We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer...
  28. ncbi request reprint Understanding the utility of adjuvant systemic therapy for primary breast cancer
    C L Loprinzi
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:972-9. 2001
    ..To date, there has not been any widely available method for estimating the benefits from adjuvant systemic therapy, in terms of long-term disease-free survival probabilities, in patients with primary breast cancer...
  29. ncbi request reprint Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7
    Charles L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1409-14. 2006
    ..This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes...
  30. ncbi request reprint Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5
    Charles L Loprinzi
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:308-12. 2007
    ..No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash control with an antidepressant alone...
  31. ncbi request reprint Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 17:3299-306. 1999
    ..The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia...
  32. ncbi request reprint Treatment of hot flushes in breast and prostate cancer
    Kerin B Adelson
    Department of Medicine, The Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Expert Opin Pharmacother 6:1095-106. 2005
    ..The most promising agents act on the CNS and include selective serotonin reuptake inhibitors, as well as venlafaxine and gabapentin...
  33. ncbi request reprint Lack of effect of coumarin in women with lymphedema after treatment for breast cancer
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    N Engl J Med 340:346-50. 1999
    ..Coumarin has been reported to be effective for the treatment of women with lymphedema; we undertook a study in which we attempted to replicate those findings...
  34. ncbi request reprint Methodologic lessons learned from hot flash studies
    J A Sloan
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:4280-90. 2001
    ..CONCLUSION: Given the data gained from these experiences, we can plan and carry out more efficient trials to identify efficacious agents for the reduction of hot flash activity...
  35. ncbi request reprint A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index
    J A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 19:3539-46. 2001
    ..The objective was to produce a simple, practical, stratification factor for phase III oncology clinical trials involving patients with advanced malignant disease...
  36. pmc Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB
    Amanda R Moraska
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Support Oncol 8:128-32. 2010
    ..These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572)..
  37. ncbi request reprint Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer
    J N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:1642-9. 1999
    ..Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus letrozole was less than expected...
  38. ncbi request reprint Sex differences in fluorouracil-induced stomatitis
    J A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 18:412-20. 2000
    ....
  39. ncbi request reprint Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy
    Julie E Hammack
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Pain 98:195-203. 2002
    ..Cross-validation sensitivity analysis of results support the conclusion that nortriptyline provides modest improvement at best over placebo in terms of chemotherapy-related neuropathy...
  40. ncbi request reprint Newer antidepressants and other nonhormonal agents for the treatment of hot flashes
    Domingo G Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Compr Ther 31:224-36. 2005
    ..This article reviews the clinical development of nonhormonal agents as alternatives to hormonal therapy for the management of hot flashes...
  41. ncbi request reprint Symptom management in premenopausal patients with breast cancer
    Charles L Loprinzi
    Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Lancet Oncol 9:993-1001. 2008
    ..Although some effective treatments can counteract symptoms related to cancer or treatments, research is needed to expand evidence-based care in premenopausal survivors of breast cancer...
  42. ncbi request reprint Pilot evaluation of citalopram for the relief of hot flashes
    Debra L Barton
    Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 1:47-51. 2003
    ..This pilot trial suggests that citalopram may be an effective non-hormonal treatment for hot flashes in women who can tolerate it...
  43. ncbi request reprint Levetiracetam for the treatment of hot flashes: a phase II study
    Susan Thompson
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Support Care Cancer 16:75-82. 2008
    ..The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors...
  44. ncbi request reprint Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1
    Barbara A Pockaj
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:2836-41. 2006
    ..Hot flashes can cause significant morbidity in postmenopausal women undergoing or finished with breast cancer treatment. Black cohosh has been used to treat hot flashes, but definitive clinical data about efficacy have been equivocal...
  45. ncbi request reprint Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy
    H J Long
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905
    Am J Clin Oncol 11:524-7. 1988
    ..Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin...
  46. ncbi request reprint A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer
    D T Ransom
    Mayo Clinic, Rochester, Minnesota 55905
    Am J Clin Oncol 14:45-8. 1991
    ..01). Among the 23 patients with measurable and/or evaluable disease there were five complete responses (22%) and nine partial responses (39%), with a median time to treatment failure of 29 weeks. The overall median survival was 19 months...
  47. ncbi request reprint Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation
    A Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 92:629-33. 2001
    ..Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated...
  48. ncbi request reprint Pilot evaluation of bupropion for the treatment of hot flashes
    Domingo G Perez
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Palliat Med 9:631-7. 2006
    ..These data suggest that bupropion should not be further investigated as a remedy for hot flashes...
  49. pmc Coprescription of tamoxifen and medications that inhibit CYP2D6
    Kostandinos Sideras
    Department of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
    J Clin Oncol 28:2768-76. 2010
    ....
  50. ncbi request reprint Pilot evaluation of mirtazapine for the treatment of hot flashes
    Domingo G Perez
    Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 2:50-6. 2004
    ....
  51. ncbi request reprint Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas
    Stephan D Thome
    Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:913-7. 2002
    ....
  52. ncbi request reprint Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Sharlene Gill
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:1797-806. 2004
    ....
  53. ncbi request reprint Current management of cancer-associated anorexia and weight loss
    A Jatoi
    Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 15:497-502, 508; discussion 508-10. 2001
    ....
  54. doi request reprint Chemotherapy-induced peripheral neuropathy: prevention and treatment
    D R Pachman
    Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 90:377-87. 2011
    ..Finally, there is a lack of evidence of effective treatments for the paclitaxel acute pain syndrome (P-APS), which appears to be caused by neurologic injury...
  55. ncbi request reprint Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Support Care Cancer 10:71-5. 2002
    ..Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss...
  56. pmc Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer
    Stephanie L Hines
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:1047-53. 2009
    ..Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer...
  57. ncbi request reprint A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
    Robert S Sandler
    Department of Medicine, University of North Carolina, Chapel Hill 27599 7555, USA
    N Engl J Med 348:883-90. 2003
    ..Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers...
  58. ncbi request reprint North Central Cancer Treatment Group--achievements and perspectives
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 35:530-44. 2008
    ....
  59. doi request reprint High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay
    Hongzhi Zou
    Miles and Shirley Fiterman Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 136:459-70. 2009
    ..We developed a digital melt curve (DMC) assay to quantify low-abundance mutations in stool samples for detection of colorectal neoplasms and compared this test with other approaches...
  60. pmc Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
    ..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
  61. ncbi request reprint Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:2802-8. 2008
    ..Based on such data, a multicenter double-blind, placebo-controlled, randomized trial was conducted to evaluate the effect of lamotrigine on pain and other neuropathic symptoms due to chemotherapy-induced peripheral neuropathy (CIPN)...
  62. ncbi request reprint Making sense of the evidence regarding nonhormonal treatments for hot flashes
    Debra Barton
    Clin J Oncol Nurs 8:39-42. 2004
    ..This algorithm includes nonhormonal options of the antidepressants available in addition to gabapentin, an antiseizure medication. A short review of the evidence for possible complementary therapies also is included...
  63. ncbi request reprint Physical activity in patients with advanced-stage cancer actively receiving chemotherapy
    Matthew M Clark
    Department of Psychiatry and Psychology, Cancer Treatment Unit, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Support Oncol 5:487-93. 2007
    ..Future research will investigate how these findings may be incorporated into physical activity interventions for advanced-stage oncology patients receiving medical treatment...
  64. ncbi request reprint Pathophysiology and treatment of hot flashes
    Tait D Shanafelt
    Department of Oncology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1207-18. 2002
    ..The use of clonidine, methyldopa, and belladonna should be discouraged because of their modest efficacy and adverse effects...
  65. pmc Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)
    Aminah Jatoi
    Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Oncologist 15:1016-22. 2010
    ..Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes...
  66. pmc Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9
    Debra L Barton
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:3278-83. 2010
    ..Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief...
  67. pmc A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
    Debra L Barton
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 19:833-41. 2011
    ..The purpose of this double-blind randomized placebo-controlled trial was to evaluate a novel compounded topical gel for this problem...
  68. ncbi request reprint A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:1396-403. 2007
    ....
  69. pmc Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy
    Stephanie L Hines
    Mayo Clinic Florida, Jacksonville, FL 32224, USA
    Breast 19:92-6. 2010
    ..Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole...
  70. ncbi request reprint Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:567-73. 2002
    ..To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia...
  71. ncbi request reprint A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)
    Aminah Jatoi
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Lung Cancer 68:234-9. 2010
    ....
  72. pmc The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)
    Debra L Barton
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Support Oncol 9:24-31. 2011
    ..However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with valerian exploring physiologic effects in oncology symptom management may be warranted...
  73. pmc Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA
    Debra L Barton
    Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 18:179-87. 2010
    ..This pilot trial sought to investigate whether any of three doses of American ginseng (Panax quinquefolius) might help cancer-related fatigue. A secondary aim was to evaluate toxicity...
  74. pmc Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
    Ann E Kearns
    Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 18:321-8. 2010
    ..The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer...
  75. pmc Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
    Stephanie L Hines
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 117:603-9. 2009
    ..Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen...
  76. ncbi request reprint A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients
    Aminah Jatoi
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 12:859-63. 2004
    ..The safety and pharmacokinetics of infliximab in combination with docetaxel, a commonly used chemotherapy agent for non-small-cell lung cancer, were explored in this pilot study...
  77. ncbi request reprint Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Ther 13:291-7. 2006
    ..Quality-of-life measures did not show any differences between the 2 groups. This study showed no evidence of benefit from flutamide as a chemoprevention agent in men with HGPIN...
  78. ncbi request reprint Centrally active nonhormonal hot flash therapies
    Charles L Loprinzi
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Med 118:118-23. 2005
    ..The most efficacious and clinically appropriate agents for use are newer antidepressants and gabapentin. Continued evaluation of the efficacy and toxicity of these agents is ongoing...
  79. ncbi request reprint Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    Clin Breast Cancer 6:425-32. 2005
    ..The efficacy and tolerability of 2 different schedules of paclitaxel/carboplatin/trastuzumab for HER2-overexpressing metastatic breast cancer (MBC) were evaluated in this parallel multicenter phase II trial...
  80. ncbi request reprint Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine
    Charles L Loprinzi
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Palliat Med 8:924-30. 2005
    ....
  81. ncbi request reprint Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention
    Ivana T Croghan
    Nicotine Research Center, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:186-95. 2007
    ..To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention...
  82. ncbi request reprint A critical review of complementary therapies for cancer-related fatigue
    Amit Sood
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Integr Cancer Ther 6:8-13. 2007
    ..To review the available literature on the use of complementary and alternative medicine (CAM) treatments for cancer-related fatigue with an aim to develop directions for future research...
  83. ncbi request reprint Pilot evaluation of black cohosh for the treatment of hot flashes in women
    Barbara A Pockaj
    Department of Surgery, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Cancer Invest 22:515-21. 2004
    ..Hot flashes cause significant morbidity in postmenopausal women, including women with breast cancer. We undertook a pilot study to estimate the effectiveness of black cohosh to reduce hot flashes...
  84. ncbi request reprint Pilot evaluation of flaxseed for the management of hot flashes
    Sandhya Pruthi
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Soc Integr Oncol 5:106-12. 2007
    ..This study suggests that dietary therapy decreases hot flash activity in women not taking estrogen therapy. This reduction is greater than what would be expected with placebo...
  85. ncbi request reprint The prevalence of weight concerns in a smoking abstinence clinical trial
    Matthew M Clark
    Mayo Clinic Mayo Building W11, 200 First Street, SW, Rochester, MN 55905, USA
    Addict Behav 31:1144-52. 2006
    ..Additionally, being weight concerned may impact the short-term success rates of stopping smoking using pharmacotherapy...
  86. ncbi request reprint An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort
    Aminah Jatoi
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:2469-76. 2004
    ..This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA...
  87. ncbi request reprint Chemotherapy-induced ovarian failure: manifestations and management
    Julian R Molina
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drug Saf 28:401-16. 2005
    ....
  88. pmc Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 79:1460-6. 2011
    ..A two-arm, double-blind, randomized trial was performed to evaluate the effect of 0.1% mometasone furoate (MMF) on acute skin-related toxicity in patients undergoing breast or chest wall radiotherapy...
  89. ncbi request reprint Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 12:640-4. 2004
    ..As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome...
  90. pmc Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
    ..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...
  91. ncbi request reprint Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1491-8. 2002
    ..After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken...
  92. doi request reprint Palliative communications: addressing chemotherapy in patients with advanced cancer
    K C Kadakia
    Division of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Ann Oncol 23:29-32. 2012
    ..Compassionate and honest communication about the use of chemotherapy can facilitate better patient care. This manuscript will explore communication issues regarding palliative-intent chemotherapy...
  93. ncbi request reprint An update: cancer-associated anorexia as a treatment target
    A Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Clin Nutr Metab Care 4:179-82. 2001
    ..To date, however, palliative options remain limited. Megestrol acetate and dexamethasone provide only modest relief. Novel agents such as thalidomide, adenosine triphosphate, and other cytokine inhibitors merit further investigation...
  94. ncbi request reprint Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity
    C L Loprinzi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905
    Cancer Invest 8:459-65. 1990
    ..There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops...
  95. pmc Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5
    Sherry L Wolf
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 28:5182-7. 2010
    ..This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS...
  96. pmc Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
    Axel Grothey
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 29:421-7. 2011
    ..In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT...
  97. ncbi request reprint Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial
    Kostandinos Sideras
    Division of Hematology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:758-67. 2006
    ..To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer...
  98. ncbi request reprint Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
    Thomas E Witzig
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:2606-17. 2005
    ..To determine whether weekly epoetin alfa could improve hemoglobin (HgB) levels, reduce RBC transfusions, and improve quality of life (QOL) in patients with advanced cancer and with anemia after receiving myelosuppressive chemotherapy...
  99. ncbi request reprint Stellate-ganglion block: a new treatment for hot flushes?
    Charles L Loprinzi
    Lancet Oncol 9:506-7. 2008
  100. ncbi request reprint Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3
    Debra L Barton
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Natl Cancer Inst 99:672-9. 2007
    ..Transdermal testosterone therapy has been associated with increased libido among estrogen-replete women who report low libido...
  101. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...

Research Grants10

  1. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 1999
    ..abstract_text> ..
  2. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Charles Loprinzi; Fiscal Year: 2006
    ..abstract_text> ..
  3. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Charles Loprinzi; Fiscal Year: 2005
    ..abstract_text> ..
  4. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
    ..abstract_text> ..
  5. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2002
    ..abstract_text> ..
  6. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2001
    ..abstract_text> ..
  7. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2000
    ..abstract_text> ..
  8. CAPITATION
    Charles Loprinzi; Fiscal Year: 2007
    ..Funding is requested for this submission to support 375 total accruals at all non-CCOP NCCTG sites at the current rate of $2,000 each, for a total request of $750,000. ..